Alzinova AB (publ)

Stockholm Stock Exchange ALZ.ST

Alzinova AB (publ) Interest Coverage Ratio for the year ending December 31, 2023: -168.59

Alzinova AB (publ) Interest Coverage Ratio is -168.59 for the year ending December 31, 2023, a 87.49% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Alzinova AB (publ) Interest Coverage Ratio for the year ending December 31, 2022 was -1,348.12, a -485.44% change year over year.
Alzinova AB (publ) Interest Coverage Ratio for the year ending December 31, 2021 was -230.27, a 98.37% change year over year.
Alzinova AB (publ) Interest Coverage Ratio for the year ending December 31, 2020 was -14,142.85, a -1,322.42% change year over year.
Alzinova AB (publ) Interest Coverage Ratio for the year ending December 31, 2019 was -994.28, a -219.20% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

Stockholm Stock Exchange: ALZ.ST

Alzinova AB (publ)

CEO	Dr. Tord Labuda M.Sc., Ph.D.
IPO Date	Nov. 25, 2015
Location	Sweden
Headquarters	Pepparedsleden 1
Employees	5
Sector	Healthcare
Industries Biotechnology 3D Printing Pharmaceuticals Vaccines

Description

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.

Key trends

Past 5 years